Cozad Asset Management Inc. Grows Stock Holdings in CVS Health Corporation $CVS

Cozad Asset Management Inc. increased its position in shares of CVS Health Corporation (NYSE:CVS) by 272.5% in the first quarter, HoldingsChannel.com reports. The firm owned 34,791 shares of the pharmacy operator’s stock after acquiring an additional 25,451 shares during the quarter. Cozad Asset Management Inc.’s holdings in CVS Health were worth $2,499,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CVS. Caitong International Asset Management Co. Ltd lifted its holdings in CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares during the last quarter. Swiss RE Ltd. purchased a new position in shares of CVS Health in the 4th quarter valued at about $26,000. Sankala Group LLC acquired a new stake in shares of CVS Health during the 4th quarter worth about $28,000. Global Trust Asset Management LLC lifted its stake in CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after purchasing an additional 300 shares during the last quarter. Finally, Mcguire Capital Advisors Inc. acquired a new position in CVS Health in the fourth quarter valued at approximately $28,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on CVS shares. Barclays increased their price target on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Sanford C. Bernstein upped their target price on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a report on Tuesday, May 12th. Bank of America increased their target price on shares of CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Royal Bank Of Canada lifted their price target on shares of CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research note on Thursday, July 9th. Finally, Morgan Stanley upped their price objective on shares of CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Twenty-one equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $105.67.

CVS Health Price Performance

Shares of NYSE CVS opened at $104.54 on Friday. The stock has a market cap of $133.39 billion, a P/E ratio of 46.05, a P/E/G ratio of 1.02 and a beta of 0.61. CVS Health Corporation has a twelve month low of $61.19 and a twelve month high of $110.68. The stock has a 50 day moving average of $101.45 and a two-hundred day moving average of $87.04. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts forecast that CVS Health Corporation will post 7.46 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Wall Street’s generally bullish recommendations continue to support the investment case, suggesting analysts see further upside in CVS Health’s healthcare-services and pharmacy businesses. Is It Worth Investing in CVS Health Based on Wall Street’s Bullish Views?
• Positive Sentiment: CVS Health’s upcoming second-quarter results are being watched for evidence that revenue, earnings, medical costs, and other key operating metrics remain on track. The company previously reported a strong earnings beat and reaffirmed fiscal 2026 EPS guidance of $7.30 to $7.50, providing a positive fundamental backdrop. CVS Health Q2 Earnings: Wall Street’s Insights on Key Metrics
• Positive Sentiment: New availability of pet medications through CVS Pharmacy could modestly expand pharmacy traffic and customer convenience, although the financial impact is likely limited initially. Pet Medications Now Available at CVS Pharmacy

Insiders Place Their Bets

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This trade represents a 24.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is currently owned by company insiders.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.